Cephalosporins in dermatology

Clinics in Dermatology

Volumn 21, Issue 1, 2003, Pages 24-32

  Del Rosso, James Q ^a,b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAMANDOLE; CEFAMANDOLE NAFATE; CEFAPIRIN; CEFAZOLIN; CEFDINIR; CEFEPIME; CEFIXIME; CEFMETAZOLE; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFTAZIDIME; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; DICLOXACILLIN; KEFTAB; LORACARBEF; UNINDEXED DRUG; WARFARIN;

ALLERGIC REACTION; ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; CELLULITIS; CHOLELITHIASIS; DIABETIC FOOT; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TARGETING; DRUG USE; EAR INFECTION; ECZEMA; FEVER; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HUMAN; HYPOPROTHROMBINEMIA; IMPETIGO; LACTATION; LEG ULCER; LYME DISEASE; LYMPHADENOPATHY; MEMBRANE PERMEABILITY; MENINGITIS; NEPHROTOXICITY; OTITIS MEDIA; PAIN; PARONYCHIA; PENICILLIN ALLERGY; PREGNANCY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RASH; RESPIRATORY TRACT INFECTION; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN INFECTION; SKIN ULCER; STRUCTURE ACTIVITY RELATION; THROMBOPHLEBITIS; TREATMENT FAILURE; URINARY TRACT INFECTION; URTICARIA;

EID: 0037214924     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00325-5     Document Type: Article

References (78)

1. Bo G. Giusepe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect Dis. 6:(Suppl 3):2000;6-8.
2. Karchmer A.W. Cephalosporins. Mandell G.L., Bennett J.E., Dolin R. Principles and practice of infectious diseases. 5th ed:2000;274-291 Churchill-Livingstone, Philadelphia.
3. Sadick N.S. Systemic antibacterial agents. Wolverton S.E. Comprehensive dermatologic drug therapy. 1st ed:2001;31-33 WB Saunders, New York.
4. Moellering R.C., Sentochnik D.E. Cephalosporins. Gorbach S.L., Bartlett J.G., Blacklow N.R. Infectious diseases. 2nd ed:1998;185-197 WB Saunders, Philadelphia.
5. Sadick N.S. Systemic antibiotic agents. Dermatol Clin. 19:2001;1-21.
6. Marshall W.F., Blair J.E. The cephalosporins. Mayo Clin Proc. 74:1999;187-195.
7. Neu H.C. The new beta-lactamase stable cephalosporins. Ann Intern Med. 97:1982;408-419.
8. Mandell G.L., Petri W.A. Antimicrobial agents penicillins, cephalosporins and other beta-lactam antibiotics . Hardman J.G., Limbird L.E. Goodman's & Gilman's the pharmacologic basis of therapeutics. 9th ed:1996;1073-1101 McGraw-Hill, New York.
9. Craig WA, Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clin Microbiol Infect Dis. 6:(Suppl 3):2000;46-49.
10. Mazzei T., Dentico P. The pharmacokinetics of oral cephalosporins. Clin Microbiol Infect Dis. 6:(Suppl 3):2000;53-54.
11. Klepser M.E., Marangos M.N., Patel K.B., et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet. 28:1995;361-384.
12. Craft J.C., Parish L.C. Systemic antimicrobial therapy. Millikan L.E. Drug therapy in dermatology. 1st ed:2000;57-78 Marcel Dekker, New York.
13. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 22:1995;89-96.
14. McDonald P.J., Wetherall B.L., Pruul H. Postantibiotic leukocyte enhancement increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes . Rev Infect Dis. 3:1981;38.
15. Bundtzen R.W., Gerber A.U., Cohn D.L., et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 3:1987;28-29.
16. Levinson M.E. Pharmacodynamics of antimicrobial agents. Infect Dis Clin North Am. 9:1995;483-495.
17. Lorian V. Some effects of subinhibitory concentrations of antibiotics on bacteria. Bull NY Med. 51:1975;1046-1047.
18. Labia R., Morand A. Interaction of cefdinir with beta-lactamases. Drugs Exp Clin Res. 20:1994;43-48.
19. Fung-Tomc J.C., Huczko E., Stickle T., et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother. 39:1995;533-538.
20. Sultan T. In vitro activity of cefdinir (FK 482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients. Chemotherapy. 10:1994;80-91.
21. Del Rosso J.Q. Get the most from antibiotic therapy. Skin Aging. 6:2001;56-60.
22. Lipsky B.A., Berendt A.R. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 16:(Suppl 1):2000;S42-S46.
23. Cuchural G.H., Tally F.P., Jacobus N.V., et al. Comparative activities of newer beta-lactam agents against members of Bacteroides fragilis group. Antimicrob Agents Chemother. 34:1990;479-480.
24. Bisno A.L., Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med. 334:1996;240-245.
25. Sadick N.S. Current aspects of bacterial infections of the skin. Dermatol Clin. 15:1997;341-349.
26. El-Tahawy A.T. Bacteriology of diabetic foot infections. Saudi Med J. 21:2000;344-347.
27. Wilson S.E. The management of skin and skin structure infections in children, adolescents and adults a review of empiric antimicrobial therapy . Int J Clin Pract. 52:1998;414-417.
28. Nathwani D. The management of skin and soft tissue infections outpatient parenteral antibiotic therapy in the United Kingdom . Chemotherapy. 47:(Suppl 1):2001;17-23.
29. Nathwani D., Moitra S., Dunbar J., et al. Skin and soft tissue infections development of a collaborative management plan between community and hospital care . Int J Clin Practice. 52:1998;456-460.
30. Page J., Levinson M.E., Thornhill T.S., et al. Treatment of soft tissue infection with cephalexin. JAMA. 211:1970;1837-1839.
31. Tack K.J., Littlejohn T.W., Mailloux G., et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. Clin Ther. 20:1998;244-256.
32. Tack K.J., Keyserling C.H., McCarty J., et al. Study of the use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. Antimicrob Agents Chemother. 41:1997;739-742.
33. Mallory S.B. Azithromycin compared to cephalexin in the treatment of skin and skin structure infections. Am J Med. 91:1991;36S-39S.
34. Lipsky B.A., Yarbrough D.R.I.I.I., Walker F.B., et al. Ofloxacin versus cephalexin for treating skin and soft tissue infections. Int J Dermatol. 31:1992;443-445.
35. US Product Monograph. Keflex (cepalexin). In: Physicians' desk reference, Montvale, NJ: Medical Economics, 2001:1124-5. Indianapolis, IN: Dista Products.
36. Madaras-Kelly K.J., Arbogast R., Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmacotherapy. 20:2000;199-205.
37. Wiseman L.R., Benfield P. Cefprozil a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential . Drugs. 45:1993;295-317.
38. Barriere S. Review of in vitro, pharmacokinetic characteristics, safety and clinical efficacy of cefprozil, a new oral cephalosporin. Ann Pharmacother. 27:1993;1082-1089.
39. Barbhaiya R.H., Shukla U.A., Gleason C.R., et al. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother. 34:1990;1204-1209.
40. Nolen T., Conetta B.J., Durham S.J., et al. Safety and efficacy of cefprozil vs cefaclor in the treatment of mild to moderate skin and skin-structure infections. Infect Med. 9:(Suppl C):1992;56-68.
41. Parish L.C., Doyle C.A., Durham S.J., et al. Cefprozil vs cefaclor in the treatment of mild to moderate skin and skin-structure infections. Clinical Therapeutics. 14:1992;453-469.
42. Wachs G., Rogan M.P. Cefprozil vs erythromycin for mild to moderate skin and skin-structure infections. Infect Med. 9:(Suppl E):1992;57-65.
43. Solomon E., McCarty J.M., Morman M.R., et al. Comparison of cefprozil and amoxicillin/clavulanate potassium in the treatment of skin and skin-structure infections in adults. Adv Ther. 9:1992;156-165.
44. Klein J.O., McCracken G.H. Summary role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children . Pediatr Infect Dis. 19:2000;S181-183.
45. Mine Y., Kamimura T., Watanabe, et al. In vitro antibacterial activity of FK 482 (cefdinir), a new orally active cephalosporin. J Antibiotics. XLI:1988;1873-1887.
46. Cohen M.A., Joannides E.T., Roland G.E., et al. In vitro evaluation of cefdinir (FK 482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn Microbiol Infect Dis. 18:1994;31-39.
47. Guay D.R.P. Cefdinir an expanded-spectrum oral cephalosporin . Ann Pharmacother. 34:2000;1469-1477.
48. Richer M., Allard S., Manseau L., et al. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob Agents Chemother. 39:1995;1082-1086.
49. Goldstein E.J., Citron D.M., Nesbit C.A. Diabetic foot infections bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases . Diabetes Care. 19:1996;638-641.
50. Parish L.C., Jungkind D.L. Systemic antimicrobial therapy for skin and skin structure infections comparison of floxacin and ceftazidime . Am J Med. 94:(Suppl 3A):1993;166-173.
51. Schulte J.M., Schmid G.P. Recommendations for treatment of chancroid. Clin Infect Dis. 20:(Suppl 1):1995;539-546.
52. 1998 Guidelines for the treatment of sexually transmitted diseases. MMWR. 47:1998;RR-1.
53. Taylor D.N., Pitarangsi C., Escheverria P., et al. Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for treatment of chancroid in Thailand. J Infect Dis. 152:1985;1002-1003.
54. Bowmer M.I., Nsanze N., D'Costa L.J., et al. Single-dose ceftriaxone for chancroid. Antimicrob Agents Chemother. 31:1987;67-71.
55. Merianos A., Gilles M., Chuah J. Ceftriaxone in the treatment of chronic donovanosis in central Australia. Genitourin Med. 70:1994;84-86.
56. Dattwyler R.J., Halperin J.J., Volkman D.J., et al. Treatment of late Lyme borreliosis - randomized comparison of ceftriaxone and penicillin. Lancet. 1:1988;1191-1194.
57. Dattwyler R.J., Halperin J.J., Pass H., et al. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis. 155:1987;1322-1325.
58. Nadelmam R.B., Luger S.W., Frank E., et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 117:1992;273-280.
59. Physicians' Desk Reference, Medical Economics. 2001;Montvale, New Jersey.
60. Anne S., Reisman R.E. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol. 74:1995;167-170.
61. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation. 5th ed:1998;151-170 Williams & Wilkins, Baltimore.
62. US Product Monograph. Omnicef (cefdinir). In: Physicians' desk reference, Montvale, NJ: Medical Economics, Abbott Park, IL: Abbott Laboratories, 2001:478-83.
63. The transfer of drugs and other chemicals into human milk. Pediatrics. 93:1994;137-150.
64. Knowkes S.R., Shear N.H. Drug hypersensitivity syndromes. Wolverton S.E. Comprehensive dermatologic drug therapy. 1st ed:2001;876-877 WB Saunders, Philadelphia.
65. Heckbert S., Stryker W., Coltin K., et al. Serum sickness in children after antibiotic exposure estimates of occurrence and morbidity in a Health Maintenance Organization population . Am J Epidemiol. 132:1990;336-342.
66. Lowery N., Kearns G.L., Young R.A., et al. Seum-sickness like reactions associated with cefprozil therapy. J Pediatr. 125:1994;325-328.
67. Prince R.A., Villar L.A. Side-effect profiles of newer-generation cephalosporins. Drug Intell Clin Pharm. 17:1983;656-657.
68. US Product Monograph. Ceclor (cefaclor). Physicians' desk reference. Montvale, NJ: Medical Economics, Indianapolis, IN: Eli Lilly Company, 2001:1706-10.
69. Stockley I.H. Drug Interactions. 1999;126 Pharmaceutical Press, Nottingham, UK.
70. US Product Monograph. Ceclor CD (cefaclor extended release). Physicians' desk reference. Montvale, NJ: Medical Economics, San Diego, CA: Dua Pharmaceuticals, 2001:1163-5.
71. Tatro DS. Drug interactions facts. Facts and comparisons. St. Louis, 2001:294.
72. Stockley I.H. Drug interactions. 1999;128 Pharmaceutical Press, Nottingham, UK.
73. Ueno K., Tanaka K., Tsujimura K., et al. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther. 54:1993;473-475.
74. Stockley I.H. Drug Interactions. 1999;544 Pharmaceutical Press, Nottingham, UK.
75. Alvarez J.S., Del Castillo J.A.S., Ortiz M.J.A. Interaction between ciclosporin and ceftriaxone. Nephron. 59:1991;681-682.
76. Xu F., Wu Z., Zou H. Effects on renal function and cyclosporin drug concentration by combination with three cephalosporins in renal transplant patients. Zhongguo Kangshengsu Zashi. 22:1997;223-225.
77. Stockley IH. Drug Interactions. Nottingham, UK: Pharmaceutical Press, 1999:223-4.
78. Tatro DS. Drug interactions facts. Facts and comparisons, St. Louis, 2001:76.